A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various cell types. The new advance, developed through an academic-industrial partnership between The University of Texas at Austin and Sanofi, helps predict how much protein cells will produce, which can minimize the need for trial-and-error experimentation, accelerating the next generation of mRNA therapeutics.